login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
INNATE PHARMA SA-SPONS ADR (IPHA) Stock News
USA
- NASDAQ:IPHA -
US45781K2042
-
ADR
1.82
USD
0 (0%)
Last: 11/14/2025, 12:27:38 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IPHA Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Chartmill
- Mentions:
SRDX
ENGN
DAVA
CYCN
...
Get insights into the top gainers and losers of Tuesday's pre-market session.
a day ago - By: Innate Pharma SA
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
3 days ago - By: Benzinga
- Mentions:
ZYXI
OM
SNES
SLNO
...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
3 days ago - By: Benzinga
- Mentions:
SOND
MSPR
CENX
IZM
...
Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
4 days ago - By: Stocktwits
- Mentions:
CNCR
IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers
4 days ago - By: Innate Pharma SA
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
8 days ago - By: Zacks Investment Research
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
9 days ago - By: Innate Pharma SA
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
a month ago - By: Innate Pharma SA
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
2 months ago - By: Innate Pharma SA
Innate Pharma Reports First Half 2025 Business Update and Financial Results
2 months ago - By: Innate Pharma SA
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
2 months ago - By: Innate Pharma SA
Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update
2 months ago - By: Innate Pharma SA
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025
3 months ago - By: Innate Pharma SA
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025
4 months ago - By: Innate Pharma SA
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
4 months ago - By: Innate Pharma SA
Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
5 months ago - By: Innate Pharma SA
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
5 months ago - By: Innate Pharma SA
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
6 months ago - By: Innate Pharma SA
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
6 months ago - By: Innate Pharma SA
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
6 months ago - By: Innate Pharma SA
Outcome of Innate Pharma’s 2025 Annual General Meeting
6 months ago - By: Innate Pharma SA
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
6 months ago - By: Innate Pharma SA
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
6 months ago - By: Innate Pharma SA
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
6 months ago - By: Innate Pharma SA
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
6 months ago - By: Innate Pharma SA
Innate Pharma announces conference call and webcast for Q1 2025 business update
7 months ago - By: Innate Pharma SA
Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F
7 months ago - By: Innate Pharma SA
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
7 months ago - By: Innate Pharma SA
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025
7 months ago - By: Innate Pharma SA
Innate Pharma Announces €15M Investment by Sanofi
Please enable JavaScript to continue using this application.